welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
rareBlog

PTC Therapeutics Announces First Publication of Real-World Data Showing Translarna (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy

PTC Therapeutics Announces First Publication Of Real-World Data Showing Translarna (ataluren) Significantly Preserves Ability To Walk For Longer In Children With Duchenne Muscular Dystrophy
PTC Therapeutics Announces First Publication Of Real-World Data Showing Translarna (ataluren) Significantly Preserves Ability To Walk For Longer In Children With Duchenne Muscular Dystrophy

Maintaining mobility is a cornerstone of quality of life for patients and families affected by Duchenne, and results for PTC Therapeutics’ Translarna (ataluren) are showing just that.

Please read more about the STRIDE registry, showing that patients treated with Translarna are able to walk longer, stand up and climb stairs faster in real-world settings. Meaningful results!

The interim data have been published in the Journal for Comparative Effectiveness Research.

Read PTC’s full press release.